“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 07/06/2023
USD0.62
▲ −0.02 (−3.13%)
Market capitalisation
USD4m
OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.
It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.
Managing Director - Head of Content, Healthcare
Albert Weber
CFO
Oliver Schacht
CEO
Forecast net debt (US$m)
13.7
Forecast gearing ratio (%)
784
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (18.7) | (37.3) | (94.3) |
| Relative | (21.2) | (41.4) | (94.4) |
| 52 week high/low | US$12.7/US$0.6 |
OpGen is a diagnostics company focused on the identification and treatment of bacterial infections. Its portfolio of molecular diagnostic tests includes the Unyvero platform with five CE-IVD-marked tests and two FDA-cleared cartridges; Ares Genetics’ next-generation antimicrobial resistance (AMR) testing services; the 510(k) cleared Acuitas AMR Gene Panel in bacterial isolates; and ARES Genetics (NGS and bioinformatics platform). OpGen’s products are differentiated by short turnaround time, large range of pathogen detection and AMR profiling. OpGen recently announced a non-exclusive US distribution agreement with Fisher Healthcare and the submission of a De Novo application for its UTI test panel with the FDA, both key developments. The company reported 94% y-o-y top-line growth to $0.9m in Q123 and maintained FY23 revenue guidance of $4–5m.
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 4.3 | (20.4) | (35.7) | (1946.77) | N/A | N/A |
| 2022A | 2.6 | (20.6) | (25.3) | (1036.81) | N/A | N/A |
| 2023E | 4.8 | (17.9) | (20.8) | (339.13) | N/A | N/A |
| 2024E | 7.1 | (17.0) | (20.8) | (207.68) | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
